With Organic Nitrogen Containing Compound Patents (Class 514/162)
-
Publication number: 20030049255Abstract: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-1 by administering an IL-1 antagonist, such as soluble type II IL-1 receptor and/or IL-1RAcP.Type: ApplicationFiled: August 7, 2002Publication date: March 13, 2003Inventors: John E. Sims, Dirk E. Smith
-
Patent number: 6511968Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 23, 2000Date of Patent: January 28, 2003Assignee: Merck & Co., Inc.Inventor: Steven A. Nichtberger
-
Publication number: 20020176859Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing impairments involving neuronal damage, loss, or degeneration, preferably of spinal ganglion neurons, by administration of a therapeutically effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect, wherein the improvement includes administering a therapeutically effective amount of a trkB or trkC agonist to treat the ototoxicity.Type: ApplicationFiled: May 21, 2002Publication date: November 28, 2002Inventor: Wei-Qiang Gao
-
Patent number: 6482846Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.Type: GrantFiled: August 30, 2001Date of Patent: November 19, 2002Assignee: NitroMed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
-
Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions
Patent number: 6482811Abstract: This invention is directed to novel pharmaceutical compositions and kits comprising bretylium as the active ingredient, as well as methods which use such compositions and kits for preventing and/or treating conditions related to the cardiovascular system.Type: GrantFiled: November 27, 2001Date of Patent: November 19, 2002Inventors: Marvin B. Bacaner, Maurice M. Kreevoy -
Patent number: 6479456Abstract: An antimicrobial perfume compositions that contain a perfume ingredient having antimicrobial activity of at least 80% as measured by the “agar surface coating test,” the “vapor phase test,” or by the “direct spray method.” The active ingredient is grapefruit-pip, a fumitory extract, a fumaric acid or an ester of fumaric acid or lactic acid.Type: GrantFiled: June 23, 2000Date of Patent: November 12, 2002Assignee: Firmenich SAInventor: Günter Holzner
-
Patent number: 6475526Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.Type: GrantFiled: June 5, 2001Date of Patent: November 5, 2002Inventor: Jeffrey B. Smith
-
Patent number: 6472381Abstract: The invention comprises the administration of an effective amount of a tellurium compound to a patients who is afflicted with psoriasis. The tellurium compound is administered either systemically or topically to one who is afflicted with psoriasis in an amount which is effective to alleviate the symptoms of psoriasis.Type: GrantFiled: October 12, 2001Date of Patent: October 29, 2002Assignee: Biomas Inc.Inventors: Michael Albeck, Benjamin Sredni
-
Publication number: 20020151465Abstract: The role of the &egr; isozyme of protein kinase C (“PKC&egr;”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC&egr;, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC&egr; and PKC&egr;-independent analgesic agent are disclosed.Type: ApplicationFiled: January 4, 2002Publication date: October 17, 2002Inventors: Robert O. Messing, Jon D. Levine
-
Publication number: 20020137724Abstract: Oral compositions for treating and/or preventing gingivitis are provided. The compositions include at least one NSAID, thymol, methyl salicylate, menthol and eucalyptol. The NSAID, thymol, methyl salicylate, menthol and eucalyptol are present in the composition in synergistically effective amounts. The compositions can be provided in the form of, e.g., mouthwashes or toothpastes, and are not only effective against gingivitis, but can also prevent or treat halitosis and other detrimental conditions of the oral cavity.Type: ApplicationFiled: February 22, 2002Publication date: September 26, 2002Inventors: Michael Rubin, Pauline Pan, Frank Volpe
-
Publication number: 20020098185Abstract: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-18 by administering an IL-18 antagonist, such as soluble IL-18 receptor, a soluble IL-18 binding protein and/or an antibody.Type: ApplicationFiled: January 18, 2002Publication date: July 25, 2002Inventors: John E. Sims, Kendall M. Mohler, Teresa L. Born
-
Publication number: 20020091108Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.Type: ApplicationFiled: July 16, 2001Publication date: July 11, 2002Inventors: Gerhard Franckowiak, Hubert Appolt, Gregor Leifker, Hans-Peter Wirges, Wolfram Ledwoch
-
Patent number: 6383527Abstract: Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, and other valerian-related compounds, in combination with NSAIDs exhibit clinically significant pharmacological properties which implicate a treatment for acute muscular aches, strains, and sprains which occur from a localized, external insult to a particular muscle or muscle group outside of, or peripheral to, the CNS. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.Type: GrantFiled: February 22, 2001Date of Patent: May 7, 2002Assignee: NPS Pharmaceuticals, Inc.Inventors: Linda D. Artman, Manuel F. Balandrin
-
Publication number: 20020037855Abstract: The invention relates to a stabilized medicament with an amount of active ingredients containing cysteine groups and NSAID compounds, wherein a stabilization of the combination, especially the active ingredients containing the cysteine group, can be conducted with a mixture of at least three anti-oxidative components. The therapeutic and prophylactic use of this medicament stabilized in this manner lies in the field of the prevention and therapy of inflammatory diseases among the fields of medical indications.Type: ApplicationFiled: March 22, 2001Publication date: March 28, 2002Inventor: Fritz Stanislaus
-
Regulation of amyloid precursor protein (APP) expression by administration of an estrogenic compound
Patent number: 6333317Abstract: It has been discovered that lipophilic hormones that interact with cytosolic or nuclear receptors regulate APP expression and synthesis, through modification of APP mRNA stability and/or regulation of APP gene transcription and translation activities. These studies demonstrate that the treatment of brain cells with estrone or 17&bgr;-estradiol results in a reduction in the level of APP holoprotein expression, without a concomitant change in the total level of cell protein. The reduction in the level of APP holoprotein caused by estrone or 17&bgr;-estradiol is also expected to reduce the production of neurotoxic APP fragments. In as much as estrogen deficiency in postmenopausal women is associated with a higher incidence of Alzheimer's disease, this discovery opens the possibility that estrogen therapy may prevent some of the neurodegenerative and cognitive changes associated with Alzheimer's disease, aging and other disease conditions associated with such neurodegenerative and cognitive decline.Type: GrantFiled: March 27, 1998Date of Patent: December 25, 2001Assignee: Massachusettes Institute of TechnologyInventors: Robert K. K. Lee, Richard J. Wurtman -
Patent number: 6294186Abstract: The present invention relates to antimicrobial compositions which provide enhanced immediate as well as residual anti-viral and antibacterial efficacy. The antimicrobial compositions of the present invention provide previously unseen residual effectiveness against Gram negative bacteria, Gram positive bacteria, and viruses, fungi, and improved immediate germ reduction upon use. These compositions comprise: a) a safe and effective amount of a benzoic acid analog; b) a safe and effective amount of a metal salt; and c) a dermatologically acceptable carrier for the acid and salt wherein said composition has a pH of from about 1 to about 7. The invention further relates to methods of use for the present compositions as well as antimicrobial products which incorporate the compositions.Type: GrantFiled: October 19, 1999Date of Patent: September 25, 2001Inventors: Peter William Beerse, Kimberly Ann Biedermann, Steven Hardy Page, Michael Joseph Mobley, Jeffrey Michael Morgan
-
Publication number: 20010007865Abstract: The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a mammal related to supranormal intracellular enzyme activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound is activated selectively within cells having such supranormal intracellular enzyme activity.Type: ApplicationFiled: February 6, 2001Publication date: July 12, 2001Applicant: D-Pharm LTD.Inventor: Alexander Kozak
-
Patent number: 6255277Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.Type: GrantFiled: May 10, 1995Date of Patent: July 3, 2001Assignees: Brigham and Women's Hospital, NitroMed, Inc.Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
-
Patent number: 6232341Abstract: The present invention provides a topical pharmaceutical composition for wound healing, which comprises (a) borneol and (b) bismuth subgallate in effective amounts. The topical pharmaceutical composition is capable of enhancing wound healing with minor irritations to injured skin, and preventing formation of scars or granulation tissues so as to help regenerate the skin with normal tenderness and appearances.Type: GrantFiled: October 5, 1998Date of Patent: May 15, 2001Assignee: Hedonist Biochemical TechnologInventors: James J. T. Chen, Black J. B. Chen
-
Patent number: 6160018Abstract: A method of preventing or delaying the onset of symptoms of Alzheimer's Disease includes the step of administering to a patient in need of such treatment a composition having an effective Alzheimer's Disease prophylactic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.Type: GrantFiled: March 10, 1997Date of Patent: December 12, 2000Assignee: Loma Linda University Medical CenterInventors: William J. Wechter, John D. McCracken
-
Patent number: 6136804Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 12, 1999Date of Patent: October 24, 2000Assignee: Merck & Co., Inc.Inventor: Steven A. Nichtberger
-
Patent number: 6074634Abstract: The present invention provides an composition for attracting noctuid and/or other lepidopteran species. Liquid and solid formulations are provided, along with methods for their use, for controlling or eliminating noctuid and/or other lepidopteran species, and/or protecting plants susceptible to noctuid and/or other lepidopteran species damage.Type: GrantFiled: October 5, 1998Date of Patent: June 13, 2000Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Juan D. Lopez, Jr., Ted N. Shaver, Kenneth R. Beerwinkle, Peter D. Lingren
-
Patent number: 6043233Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.Type: GrantFiled: January 22, 1999Date of Patent: March 28, 2000Assignee: NitroMed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
-
Patent number: 6025395Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders so as to ameliorate the further progress of symptoms. The methods involve the administration of a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. According to indication, the present method can be applied to individuals who are currently asymptomatic but at risk of developing Alzheimer's disease, to individuals who have mild cognitive symptoms that may either denote an incipient prodrome of Alzheimer's disease or represent early symptoms (prodromal stage), or to individuals who have a clinical diagnosis of Alzheimer's disease.Type: GrantFiled: April 14, 1997Date of Patent: February 15, 2000Assignee: Duke UniversityInventors: John C. S. Breitner, Kathleen A. Welsh-Bohmer
-
Patent number: 6011067Abstract: The present invention deals with the combination of several synergistic antioxidants including enzymatic co-factors as adjuncts to therapy of desquamating inflammatory disorders, such as psoriasis. These topical compositions are aimed to neutralize free radical species generated by such inflammatory conditions which are responsible for certain clinical signs and symptoms. As such, damage to skin causing destruction of elastin and collagen tissues is reduced. The present synergistic antioxidants may be combined with anti-inflammatories, including corticosteroids, anti-microbials, including zinc pyrithione, and other preparations useful in the therapy of desquamating disorders as psoriasis, seborrhoeic dermatitis and related skin and scalp conditions.Type: GrantFiled: June 11, 1999Date of Patent: January 4, 2000Assignee: Thione International, Inc.Inventor: Theodore Hersh
-
Patent number: 5968539Abstract: The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.001% to about 5% of an antimicrobial active, from about 1% to about 80% of an anionic surfactant, from about 0.1% to about 12% of a proton donating agent; and from about 3% to about 98.899% of water, wherein the composition is adjusted to a pH of from about 3.0 to about 6.0, wherein the rinse-off antimicrobial cleansing composition has a Gram Negative Residual Effectiveness Index of greater than about 0.3, and wherein the rinse-off antimicrobial cleansing composition has a Mildness Index of greater than 0.3. The invention also encompasses methods for cleansing skin and providing residual effectiveness versus Gram negative bacteria using these products.Type: GrantFiled: June 4, 1997Date of Patent: October 19, 1999Assignee: Procter & Gamble CompanyInventors: Peter William Beerse, Jeffrey Michael Morgan, Kathleen Grieshop Baier, Wei Cen, Theresa Anne Bakken
-
Patent number: 5948443Abstract: The present invention pertains generally to the field of Public Health, including the prevention and treatment of coronary heart disease which is currently the first cause of death in the American population. More specifically, the present invention concerns a total modular system of multivitamin and mineral supplementation composed of 7 distinct modules for improving public health by insuring adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to, for example, lifestyle factors and common inadequate dietary patterns. A module, as used herein throughout, is defined as a separate and distinct combination of vitamin-mineral and other health promoting compounds which are directed to specific target populations. The formulations of the present invention which, when combined in one capsule or tablet or as separate modules, exert a joint and enhancing effect on the major pathogenetic factors involved in the atherosclerotic process.Type: GrantFiled: February 21, 1997Date of Patent: September 7, 1999Assignee: Medical Doctor's Research Institute, Inc.Inventors: Patricia A. Riley, George Christakis
-
Patent number: 5919776Abstract: The present invention is directed to aminoquinolines of Formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.Type: GrantFiled: December 18, 1997Date of Patent: July 6, 1999Assignee: Merck & Co., Inc.Inventors: William K. Hagmann, Martin S. Springer
-
Patent number: 5827886Abstract: A composition and method of using it for ameliorating inflammatory reactions and painful and other symptoms of the diseases of arthritis, lumbago, low back pain, myalgias and neuralgias. The composition includes reduced glutathione, a selenoamino acid and an anesthetic, such as capsaicin, in a suitable carrier for topical application.Type: GrantFiled: May 7, 1997Date of Patent: October 27, 1998Assignee: Thione International, Inc.Inventor: Theodore Hersh
-
Patent number: 5776920Abstract: A preparation containing salicylic acid, lactic acid and urea in a moisturizing base, which can be used for the topical treatment of psoriasis.Type: GrantFiled: August 2, 1995Date of Patent: July 7, 1998Inventor: Ruth Quarles
-
Patent number: 5750559Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.Type: GrantFiled: August 5, 1994Date of Patent: May 12, 1998Assignee: Sebastiano BiancoInventor: Sebastiano Bianco
-
Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
Patent number: 5747532Abstract: In accordance with the present invention, there are provided combinational therapeutic methods for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the enzymes responsible for nitric oxide production is inhibited), the present invention employs a combination of inactivation (or inhibition) and scavenging approach whereby the stimulus of nitric oxide synthase expression is inactivated, or the production thereof is inhibited, and overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complexes render the stimulus of nitric oxide synthase expression inactive (or inhibit the production thereof), and nitric oxide harmless.Type: GrantFiled: November 21, 1995Date of Patent: May 5, 1998Assignee: Medinox, Inc.Inventor: Ching-San Lai -
Patent number: 5728392Abstract: Cosmetic or dermatological compositions containing at least one anti-aging active agent having an irritant effect, a cosmetically or dermatologically acceptable medium, and in addition, as an agent mollifying the irritant effect, a ceramide of the following formula (I): ##STR1## wherein A is ##STR2## R.sub.1 is a saturated or unsaturated, linear or branched C.sub.10 to C.sub.26 alkyl group;R.sub.2 is a saturated or unsaturated, linear or branched C.sub.12 to C.sub.32 alkyl group;R.sub.3 is H or --CO--CHOH--R.sub.2 ; andn is 0 or 1,are effective for combating the aging of skin and at the same time exhibit a reduced tendency to cause smarting, itching, or a sensation of tightness when applied to the skin.Type: GrantFiled: June 5, 1996Date of Patent: March 17, 1998Assignee: L'OrealInventors: Lucien Aubert, Francoise Gagnebien-Cabanne
-
Patent number: 5710141Abstract: The present invention relates to methods for treating acne and related pilosebaceous disorders with a safe and effective amount of salicylic acid and pantothenic acid or a pantothenic acid derivative. This combination of materials is found to be less irritating and drying to the skin than salicylic acid alone.Type: GrantFiled: September 30, 1996Date of Patent: January 20, 1998Assignee: The Procter & Gamble CompanyInventors: Spencer Guang Lin, Kathleen Grieshop Baier
-
Patent number: 5643960Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The method involves the administration to individuals at risk of developing the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders that involves the use of such agents.Type: GrantFiled: April 15, 1994Date of Patent: July 1, 1997Assignee: Duke UniversityInventors: John C. S. Breitner, Kathleen A. Welsh
-
Patent number: 5612324Abstract: The present invention relates to methods for treating acne and related pilosebaceous disorders with a safe and effective amount of salicylic acid and pantothenic acid or a pantothenic acid derivative. This combination of materials is found to be less irritating and drying to the skin than salicylic acid alone.Type: GrantFiled: April 12, 1995Date of Patent: March 18, 1997Assignee: The Procter & Gamble CompanyInventors: Spencer Guang Lin, Kathleen G. Baier
-
Patent number: 5589178Abstract: Cosmetic or dermatological compositions containing at least one anti-aging active agent having an irritant effect, a cosmetically or dermatologically acceptable medium, and in addition, as an agent mollifying the irritant effect, a ceramide of the following formula (I): ##STR1## R.sub.1 is a saturated or unsaturated, linear or branched C.sub.10 to C.sub.26 alkyl group;R.sub.2 is a saturated or unsaturated, linear or branched C.sub.12 to C.sub.32 alkyl group;R.sub.3 is H or --CO--CHOH--R.sub.2 ; andn is 0 or 1.Type: GrantFiled: December 30, 1994Date of Patent: December 31, 1996Assignee: L'OrealInventors: Lucien Aubert, Francoise Gagnebien-Cabanne
-
Patent number: 5389621Abstract: A method of enhancing the anticoagulant effect of aspirin is disclosed, wherein salicylamide is coadministered. Salicylamide is essentially without anticoagulant effects of its own. A normal dose of salicylamide, approximately 30 mg to about 3.0 grams administered daily, or about 3 to 9 mg/kg body weight, can increase the anticoagulant effect of aspirin. This is particularly desirable in patients who are undergoing long-term anticoagulant therapy, e.g., cardiac patients.Type: GrantFiled: February 18, 1994Date of Patent: February 14, 1995Assignee: University of Medicine and Dentistry of New JerseyInventors: Mohamed S. Abdel-Rahman, Maged M. Rizk
-
Patent number: 5366967Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.Type: GrantFiled: May 21, 1993Date of Patent: November 22, 1994Assignee: Hoechst AktiengesellschaftInventor: Sebastiano Bianco
-
Patent number: 5192753Abstract: This invention pertains to the novel use of anti-rheumatoid arthritic drugs in the treatment of dementia. A method of treating dementia in human beings which comprises administering to the human being a therapeutic amount of a non-steroidal anti-inflammatory drug (NSAID) which has the ability to inhibit prostaglandin synthesis in the human being.Type: GrantFiled: April 23, 1991Date of Patent: March 9, 1993Inventors: Patrick L. McGeer, Joseph Rogers, John Sibley, Edith McGeer
-
Patent number: 5175152Abstract: A method of delivering ephedrine base in vapor form from a composition containing the ephedrine base and an alkyl salicylate. Methyl salicylate is the preferred alkyl salicylate. Optional ingredients in the composition include aromatic compounds such as menthol, camphor, and various other essential oils. The method is particularly useful in the treatment of nasal congestion and bronchial asthma. A preferred means of delivering the ephedrine base in vapor form in the treatment of nasal congestion and bronchial asthma is a vapor inhaler.Type: GrantFiled: September 28, 1990Date of Patent: December 29, 1992Inventor: Nikhilesh N. Singh
-
Patent number: 5081148Abstract: The invention relates to a therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein, an effective amount either, of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.4 stant for H or CH.sub.3 or C.sub.2 H.sub.5,R.sub.2 stands for H or NO.sub.2 andR.sub.3 stands for NHR.sub.4 or CH.sub.3 or C.sub.2 H.sub.5alone or of a mixture of said compound with a cyclooxygenase blocker.Type: GrantFiled: December 19, 1990Date of Patent: January 14, 1992Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Pierre Braquet, Pierre-Etienne Chabrier de Lassauniere, Jean-Michel Guillon, Michel Auguet
-
Patent number: 5071842Abstract: A nonsteroidal anti-inflammatory drug composition containing as protectants against gastrointestinal injury, H.sub.1 blockers, H.sub.2 blockers, beta-adrenergic agonists, or combinations thereof, and an alkalizing agent and a process for administering such compositions.Type: GrantFiled: December 21, 1989Date of Patent: December 10, 1991Assignee: Bristol-Myers Squibb CompanyInventors: Alison B. Lukacsko, Joseph J. Piala
-
Patent number: 5055461Abstract: Disclosed are oral anesthetic pharmaceutical compositions comprising: (a) from about 0.02% to about 25% of a pharmaceutically acceptable acid salt of a .beta.-aminopropiophenone, such as dyclonine HCl; (b) from about 0.02% to about 20% of saccharin; and (c) from about 1% to about 99% of a pharmaceutically acceptable oral carrier. Also provided are methods for providing an anesthetic effect in humans or animals which comprises orally administering to said human or animal a safe and effective amount of these pharmaceutical compositions. Also provided is a novel process for the manufacture of anesthetic lozenges containing a .beta.-aminopropiophenone along with saccharin.Type: GrantFiled: March 21, 1990Date of Patent: October 8, 1991Assignee: Richardson-Vicks Inc.Inventors: William J. Kelleher, William J. McClintock
-
Patent number: 5037815Abstract: A pharmaceutical composition and process for administering non-steroidal drugs which are protected againsts injury to the gastrointestinal tract by a combination of certain H.sub.1 - and H.sub.2 -receptor blockers.Type: GrantFiled: September 8, 1988Date of Patent: August 6, 1991Assignee: Bristol-Myers Squibb Co.Inventors: Alison B. Lukacsko, Randy J. Koslo, Joseph J. Piala
-
Patent number: 4988683Abstract: This invention relates to the field of pharmaceutical chemistry and more precisely to the field of galenical pharmacy.It refers to new pharmaceutical compositions intended for the buccal tract, the active ingredient of which is lysine acetylsalicylate in association or mixed with one or several excipients and/or diluents adapted to achieve a pharmaceutical form which may be sucked or chewed. A process for the production of said pharmaceutical composition is also described.Type: GrantFiled: July 20, 1989Date of Patent: January 29, 1991Inventor: Jerome Corbiere
-
Patent number: 4970202Abstract: A pharmaceutical composition for treating an inflammatory condition contains a non-steroidal anti-inflammatory drug (NSAID) and a physiologically acceptable aromatic hydroxysulphonic acid. The two components may be for simultaneous, separate or sequential use. Administration of the two components, for example of aspirin with ethamsylate, reduces the damage which the NSAID does to the gastrointestinal tract while having no deleterious effect on the anti-inflammatory activity.Type: GrantFiled: July 20, 1989Date of Patent: November 13, 1990Assignee: Delandale Laboratories LimitedInventor: David J. Trigger
-
Patent number: 4965065Abstract: A pharmaceutical composition and process for administering non-steroidal anti-inflammatory drugs which are protected against injury to gastrointestinal tract by beta adrenergic agonists.Type: GrantFiled: February 6, 1987Date of Patent: October 23, 1990Assignee: Bristol-Myers Squibb CompanyInventors: Alison B. Lukacsko, Randy J. Koslo
-
Patent number: 4933330Abstract: A pharmaceutical composition for use in the treatment of psoriasis comprises 4-aminosalicylic acid (4-ASA) or 5-aminosalicylic acid (5-ASA) or a functional derivative thereof, said pharmaceutical composition being in a form suitable for topical administration. Furthermore, 4- or 5-ASA or a functional derivative thereof are used for the manufacture of pharmaceutical compositions for treating psoriasis, atopic dermatitis, allergic dermatitis, contact dermatitis, seborrhoic dermatitis, or acne diseases. The derivatives have the formulae: ##STR1## where W is COOX, wherein X is H, Li, Na, K, Mg.sub.0.5, Ca.sub.0.5, Zn.sub.0.5, Al.sub.0.33, Fe(II).sub.0.5, Fe(III).sub.0.33, NH.sub.4, NH.sub.3 R.sup.1, NH.sub.2 R.sup.1.sub.2, NHR.sup.1.sub.3, NR.sup.1.sub.4, or R.sup.1, where R.sup.1 is substituted or unsubstituted C.sub.1-6 -alkyl, aryl-C.sub.1-4 -alkyl, or heteroaryl-C.sub.1-4 -alkyl; or COX, where X is NR.sup.1 R.sup.1', where R.sup.1' has the same meaning as R.sup.1 defined above and R.sup.1 and R.sup.Type: GrantFiled: March 30, 1988Date of Patent: June 12, 1990Assignee: DAK-LaboratorietInventors: Anne P. Jorgensen, Torkil Menne
-
Patent number: 4927855Abstract: The levorotatory isomer of benzhydrylsulfinylacetamide has useful pharmaceutical activity on the central nervous system, particularly as an antidepressant and stimulant in the treatment of hypersomnia and Alzheimer's disease.Type: GrantFiled: January 28, 1987Date of Patent: May 22, 1990Assignee: Laboratoire L. LafonInventor: Louis Lafon